As of 2017, aBSI is provided as a secure and compliant web application readily available from a web browser by logging in to, www.bonescanindex.com. In Europe, the device is CE-marked according to MDD 93/42 EEC, and is available for clinical use in Austria, Denmark, France, Germany, Ireland, Netherlands, Sweden, Switzerland, UK. In the United States, aBSI is available for investigational use only.
- Ulmert D, et al. A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol. 2012.
- Armstrong AJ et al. Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2018.
BONENAVI, the platform to calculate bone scan index in Japan, was launched 2011 with partner FUJIFILM RI Pharma. The platform is developed and validated for Japanese patient population. Since its launch in 2011, nearly 900 hospitals have incorporated BONENAVI in their regular clinical workflow. Illustrative BONENAVI reports are used in discussing treatment evaluation with patients. The society of nuclear medicine in Japan recommends bone scan index for use in metastatic prostate cancer to assess metastatic burden in bone. The availability of BONENAVI has generated clinical value of the bone scan in prostate cancer.
FUJIFILM currently holds the exclusive rights of BONENAVI in Japan.